Ondansetron is widely distributed (volume of distribution approximately 160L) and binds moderately (70 to 76%) to plasma proteins; the elimination half-life averages approximately 3
Contraindicated
Highlights of Prescribing Information These highlights do not include all the information needed to use ZOFRAN safely and effectively
This
Zofran, Zuplenz (ondansetron) dosing, indications, interactions, adverse effects, and more
On This Page Indications and Usage Dosage and Administration Dosage Forms and Strengths Contraindications Warnings and
Recommended dose: 8 mg orally twice a day, with the first dose administered 30 minutes before the start of chemotherapy and the subsequent
com on Aug 4
Each 8-mg ZOFRAN tablet for oral administration contains ondansetron hydrochloride dihydrate equivalent to 8 mg of ondansetron
2012; 21
1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Chemotherapy
In
Among women receiving outpatient nursing services, we identified those diagnose
Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism
dose of ondansetron was followed by oral administration of ondansetron
tissue of the upper chest, upper back, abdomen, upper arms or thigh Improved Outcome with Chronic Subcutaneous Infusion of Ondansetron for Intractable Nausea and Vomiting
Ondansetron by subcutaneous infusion
Compared with oral ondansetron, subcutaneous dosing resulted in an increased rate and extent of absorption
Reporting suspected adverse effects
Eye Disorders: Transient blindness (predominantly during IV administration) reported to resolve within a few minutes up to 48 hr; transient blurred vision
Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats
ZOFRAN is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2
The route of administration and dose of Ondansetron 2mg/ml Solution for Injection or infusion should be flexible in the range of 8-32 mg a day and selected as shown below
Then administer 8 mg twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy
There is no experience beyond first-day administration of ondansetron in these patients [see CLINICAL PHARMACOLOGY]
Introduction
Compared with oral ondansetron, subcutaneous dosing resulted in an increased rate and extent of absorption
Medications may be administered through a primary line that is already infusing fluids or through a saline lock inserted into a patient’s vein with direct access to the bloodstream